Yesterday at the American Academy of Neurology annual conference we presented advancements in trial screening for ALTITUDE-AD, our Phase 2 study of sabirnetug targeting early #AlzheimersDisease.

#AAN25 #AANAM #AAN202

🔗Click to see the full presentation: acumenpharm.com/document-lib...